NASDAQ:NLNK - NewLink Genetics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$10.80
▼ -0.12 (-1.10%)
Get New NewLink Genetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NLNK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NLNK

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for NewLink Genetics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $10.80.

This chart shows the closing price for NLNK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in NewLink Genetics. This rating has held steady since December 2020, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
1/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
6/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
9/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/3/2020Bank of AmericaDowngradeNeutral ➝ UnderperformLow
2/28/2019Robert W. BairdLower Price TargetNeutral ➝ Neutral$5.00 ➝ $4.00High
1/3/2019Bank of AmericaDowngradeNeutral ➝ UnderperformMedium
11/2/2018Bank of AmericaLower Price TargetNeutral ➝ Neutral$6.00 ➝ $5.00Low
8/1/2018Stifel NicolausDowngradeBuy ➝ Hold$8.00 ➝ $4.00High
5/4/2018Stifel NicolausLower Price TargetBuy ➝ Buy$21.00 ➝ $8.00High
5/3/2018Cantor FitzgeraldSet Price TargetHold$7.00High
4/16/2018Cantor FitzgeraldSet Price TargetHold$7.00High
4/12/2018Jefferies Financial GroupReiterated RatingHoldHigh
4/9/2018Robert W. BairdDowngradeOutperform ➝ Neutral$22.00 ➝ $5.00High
4/9/2018Cantor FitzgeraldDowngradeOverweight ➝ Neutral$26.00 ➝ $7.00High
4/6/2018Jefferies Financial GroupDowngradeBuy ➝ HoldLow
4/6/2018Bank of AmericaDowngradeBuy ➝ NeutralHigh
4/6/2018SunTrust BanksDowngradeBuy ➝ Hold$19.00 ➝ $5.00High
4/6/2018Cantor FitzgeraldSet Price TargetBuy$26.00High
3/2/2018Bank of AmericaLower Price TargetBuy ➝ Buy$22.00 ➝ $18.00Low
3/2/2018Stifel NicolausReiterated RatingBuy$25.00 ➝ $21.00High
3/2/2018Cantor FitzgeraldSet Price TargetBuy$26.00High
1/8/2018Cantor FitzgeraldSet Price TargetBuy$26.00Low
11/3/2017Jefferies Financial GroupLower Price TargetBuy$26.00 ➝ $25.00N/A
11/3/2017Stifel NicolausBoost Price TargetBuy$25.00 ➝ $29.00N/A
11/2/2017Cantor FitzgeraldReiterated RatingBuy$26.00N/A
10/13/2017Bank of AmericaInitiated CoverageBuy$22.00N/A
9/25/2017Cantor FitzgeraldReiterated RatingBuy$26.00Medium
9/11/2017Stifel NicolausBoost Price TargetBuy ➝ Buy$14.00 ➝ $29.00High
9/8/2017Cantor FitzgeraldReiterated RatingBuy$26.00High
9/8/2017Robert W. BairdUpgradeNeutral ➝ Outperform$8.00 ➝ $22.00Medium
9/8/2017Jefferies Financial GroupUpgradeHold ➝ Buy$7.00 ➝ $26.00High
8/25/2017Jefferies Financial GroupSet Price TargetHold$7.00Medium
7/28/2017Cantor FitzgeraldSet Price TargetBuy$26.00High
7/14/2017Jefferies Financial GroupReiterated RatingHold$7.00Low
6/8/2017Robert W. BairdDowngradeOutperform ➝ Neutral$25.00 ➝ $8.00High
6/5/2017Robert W. BairdReiterated RatingOutperform ➝ Outperform$25.00Low
6/4/2017Cantor FitzgeraldSet Price TargetBuy$32.00High
5/15/2017Jefferies Financial GroupReiterated RatingHold$18.00Medium
5/5/2017Jefferies Financial GroupReiterated RatingHold$18.00Medium
5/4/2017Cantor FitzgeraldSet Price TargetBuy$32.00Medium
4/22/2017Stifel NicolausReiterated RatingBuy$26.00Medium
4/22/2017Cantor FitzgeraldReiterated RatingOverweight$20.00 ➝ $32.00Medium
4/6/2017Jefferies Financial GroupBoost Price TargetHold$15.00 ➝ $18.00Medium
4/6/2017Stifel NicolausReiterated RatingBuy$26.00Medium
3/30/2017SunTrust BanksUpgradeHold ➝ Buy$12.00 ➝ $30.00High
3/1/2017Stifel NicolausBoost Price TargetBuy$22.00 ➝ $26.00N/A
3/1/2017Jefferies Financial GroupBoost Price TargetHold$12.00 ➝ $15.00N/A
11/3/2016Jefferies Financial GroupReiterated RatingHold$12.00N/A
10/28/2016Jefferies Financial GroupReiterated RatingHold$10.00 ➝ $12.00N/A
(Data available from 6/24/2016 forward)
NewLink Genetics logo
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.
Read More

Today's Range

Now: $10.80
Low: $10.66
High: $10.91

50 Day Range

MA: $9.07
Low: $0.89
High: $14.10

52 Week Range

Now: $10.80
Low: $0.82
High: $3.60

Volume

6,601 shs

Average Volume

547,540 shs

Market Capitalization

$403.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17

Frequently Asked Questions

What sell-side analysts currently cover shares of NewLink Genetics?

The following Wall Street sell-side analysts have issued research reports on NewLink Genetics in the last twelve months:
View the latest analyst ratings for NLNK.

What is the current price target for NewLink Genetics?

0 Wall Street analysts have set twelve-month price targets for NewLink Genetics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for NewLink Genetics in the next year.
View the latest price targets for NLNK.

What is the current consensus analyst rating for NewLink Genetics?

NewLink Genetics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NLNK.

What other companies compete with NewLink Genetics?

How do I contact NewLink Genetics' investor relations team?

NewLink Genetics' physical mailing address is 2503 SOUTH LOOP DRIVE, AMES IA, 50010. The biotechnology company's listed phone number is 515-296-5555 and its investor relations email address is [email protected] The official website for NewLink Genetics is www.newlinkgenetics.com.